Regulatory approval

Published by the Health Canada. Approved

TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic non-squamous NSCLC.

This is written in the approval document.

Citation

Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00082952.PDF. Revised December 2025. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies